The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Effect of the Affordable Medicines Facility—malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data
Abstract
Background Malaria is one of the greatest causes of mortality worldwide. Use of the most effective treatments for malaria remains inadequate for those in need, and there is concern over the emergence of resistance to these treatments. In 2010, the Global Fund launched the Affordable Medicines Facility--malaria (AMFm), a series of national-scale pilot programmes designed to increase the access and use of quality-assured artemisinin based combination therapies (QAACTs) and reduce that of artemisinin monotherapies for treatment of malaria. AMFm involves manufacturer price negotiations, subsidies on the manufacturer price of each treatment purchased, and supporting interventions such as communications campaigns. We present findings on the effect of AMFm on QAACT price, availability, and market share, 6-15 months after the delivery of subsidised ACTs in Ghana, Kenya, Madagascar, Niger, Nigeria, Uganda, and Tanzania (including Zanzibar). Methods We did nationally representative baseline and endpoint surveys of public and private sector outlets that stock antimalarial treatments. QAACTs were identified on the basis of the Global Fund's quality assurance policy. Changes in availability, price, and market share were assessed against specified success benchmarks for 1 year of AMFm implementation. Key informant interviews and document reviews recorded contextual factors and the implementation process. Findings In all pilots except Niger and Madagascar, there were large increases in QAACT availability (25·8-51·9 percentage points), and market share (15·9-40·3 percentage points), driven mainly by changes in the private for-profit sector. Large falls in median price for QAACTs per adult equivalent dose were seen in the private for-profit sector in six pilots, ranging from US$1·28 to $4·82. The market share of oral artemisinin monotherapies decreased in Nigeria and Zanzibar, the two pilots where it was more than 5% at baseline. Interpretation Subsidies combined with supporting interventions can be effective in rapidly improving availability, price, and market share of QAACTs, particularly in the private for-profit sector. Decisions about the future of AMFm should also consider the effect on use in vulnerable populations, access to malaria diagnostics, and cost-effectiveness. Funding The Global Fund to Fight AIDS, Tuberculosis and Malaria, and the Bill & Melinda Gates Foundation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two references reported on the Affordable Medicines Facility-malaria (AMFm), which provided subsidies to manufacturers of artemisinin-based combination therapies (ACT) at the global level, and which resulted in price reductions for ACTs to consumers36”
In the citing paper
“and increased availability of ACTs in various countries in Sub-Saharan Africa.36 37”
In the citing paper
“An independent evaluation of the effect of AMFm on quality-assured ACT price, availability, and market share was conducted 6–15 months after the delivery of subsidized ACTs in Ghana, Kenya, Madagascar, Niger, Nigeria, Uganda, and Tanzania (including Zanzibar).167”
From Global health 2050: the path to halving premature death by mid-century (2024) · cites this paper as [167]
In the citing paper
“In all pilots except Niger and Madagascar, there were large increases in ACT availability (25·8–51·9 percentage points), and market share (15·9–40·3 percentage points), driven mainly by changes in the private for-profit sector.”
From Global health 2050: the path to halving premature death by mid-century (2024) · cites this paper as [167]
In the citing paper
“Large falls in median price for ACTs per adult equivalent dose were seen in the private for-profit sector in six pilots, ranging from US$1·28 to $4·82.”
From Global health 2050: the path to halving premature death by mid-century (2024) · cites this paper as [167]
In the citing paper
“The market share of oral artemisinin monotherapies decreased in Nigeria and Zanzibar, the two pilots where it was more than 5% at baseline.”
From Global health 2050: the path to halving premature death by mid-century (2024) · cites this paper as [167]
In the citing paper
“The evaluators concluded that subsidies combined with supporting interventions could be effective in rapidly improving availability, price, and market share of quality-assured ACTs, particularly in the private for-profit sector.”
From Global health 2050: the path to halving premature death by mid-century (2024) · cites this paper as [167]
Citations
Cites
Developing and evaluating complex interventions: the new Medical Research Council guidance
Craig, P., Dieppe, P., Macintyre, S., Michie, S., Nazareth, I., & Petticrew, M. (2008) · BMJ · doi:10.1136/bmj.a1655 · Cited by 10,995
Developing and Evaluating Complex Interventions: New Guidance
Craig, P., Dieppe, P. A., MacIntyre, S., Michie, S., Nazareth, I., & Petticrew, M. P. (2006) · UCL Discovery (University College London) · Cited by 1,878
Demographic and Health Surveys
Larmarange, J., Vallo, R., Yaro, S., Méda, N., Ferry, B., Larmarange, J., & Ird, D. (2008) · Choice Reviews Online · doi:10.5860/choice.45-6819 · Cited by 1,455
Artemisinin resistance: current status and scenarios for containment
Dondorp, A. M., Yeung, S., White, L. J., Nguon, C., Day, N., Socheat, D., & von Seidlein, L. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2331 · Cited by 658
Chan, M. (2010) · Cited by 513
Institute of Medicine (2004) · National Academies Press eBooks · doi:10.17226/11017 · Cited by 232
Erratum: Artemisinin resistance: current status and scenarios for containment
Dondorp, A. M., Yeung, S., White, L. J., Nguon, C., Day, N., Socheat, D., & von Seidlein, L. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2385 · Cited by 221
O’Connell, K. A., Gatakaa, H., Poyer, S., Njogu, J. N., Evance, I., Munroe, E., Solomon, T., Goodman, C. A., Hanson, K., ZINSOU, C., et al. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-326 · Cited by 163
Self-citationSabot, O. J., Mwita, A., Cohen, J. M., Ipuge, Y., Gordon, M., Bishop, D., Odhiambo, M., Ward, L., & Goodman, C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006857 · Cited by 105
Self-citationKangwana, B. P., Kedenge, S. V., Noor, A. M., Alegana, V. A., Nyandigisi, A. J., Pandit, J. M., Fegan, G., Todd, J., BROOKER, S. J., Snow, R. W., et al. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000437 · Cited by 82
Self-citation
Cited by
Sorted by citations
Items 101–173 of 173
The affordable medicines facility-malaria—A success in peril
Talisuna, A. O., Adibaku, S., Amojah, C. N., Amofah, G. K., Aubyn, V. N. A., Dodoo, A. N. O., Juma, E. A., Jackou, D. H., Mkude, S., Okui, A. P., et al. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-370 · Cited by 9
Self-citationLarson, P. S., Yadav, P., Alphs, S., Arkedis, J., Massaga, J. J., Sabot, O. J., & Cohen, J. L. (2013) · BMC Health Services Research · doi:10.1186/1472-6963-13-526 · Cited by 8
Ajayi, I. O., Soyannwo, T., & Akpa, O. M. (2013) · Malaria Research and Treatment · doi:10.1155/2013/176096 · Cited by 8
A global compact to counter vaccine nationalism
Jha, P., Jamison, D. T. T., Watkins, D., & Bell, J. I. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01105-3 · Cited by 8
Watkins, D., Danforth, K., Ahmed, S., Chisholm, D., Cieza, A., Iunes, R. F., Kumar, A., Kutzin, J., Luong, J., Meessen, B., et al. (2025) · The Lancet Global Health · doi:10.1016/s2214-109x(25)00347-x · Cited by 7
Which price is right? A comparison of three standard approaches to measuring prices
Fitzpatrick, A. (2023) · Journal of Development Economics · doi:10.1016/j.jdeveco.2023.103106 · Cited by 9
Apeagyei, A. E., Cogswell, I. E., Patel, N., O’Rourke, K., Tsakalos, G., & Dieleman, J. L. (2024) · Malaria Journal · doi:10.1186/s12936-024-05165-w · Cited by 7
Comparing Decisions for Malaria Testing and Presumptive Treatment
Basu, S., Modrek, S., & Bendavid, E. (2014) · Medical Decision Making · doi:10.1177/0272989x14533609 · Cited by 7
Tesfazghi, K., Traoré, A., Ranson, H., N’Falé, S., Hill, J., & Worrall, E. (2015) · Implementation Science · doi:10.1186/s13012-016-0469-4 · Cited by 7
In the Global Fund's court: experimentation, evaluation, and the AMFm
Bump, J. B., Fan, V. Y., Lanthorn, H., & Yavuz, E. (2012) · The Lancet · doi:10.1016/s0140-6736(12)62123-0 · Cited by 7
Akoria, O., & Arhuidese, I. J. (2014) · Annals of African Medicine · doi:10.4103/1596-3519.134383 · Cited by 7
An empirical review of antimalarial quality field surveys: the importance of characterising outcomes
Grech, J., Robertson, J. A., Thomas, J., Cooper, G. M., Naunton, M., & Kelly, T. L. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.04.056 · Cited by 7
Determinants of price setting decisions on anti-malarial drugs at retail shops in Cambodia
Patouillard, E., Hanson, K., Kleinschmidt, I., Palafox, B., Tougher, S., Pok, S., O’Connell, K., & Goodman, C. A. (2015) · Malaria Journal · doi:10.1186/s12936-015-0737-9 · Cited by 6
Self-citationBerdud, M., Towse, A., & Kettler, H. E. (2016) · Oxford Review of Economic Policy · doi:10.1093/oxrep/grv039 · Cited by 6
ACTwatch Group, Phok, S., & Lek, D. (2017) · Malaria Journal · doi:10.1186/s12936-017-1807-y · Cited by 6
Thomson, R. M., Johanes, B., Festo, C., Kalolella, A., Taylor, M., Tougher, S., Yé, Y., Mann, A. G., Ren, R., Bruxvoort, K. J., et al. (2018) · BMC Health Services Research · doi:10.1186/s12913-018-2966-4 · Cited by 6
Self-citationGallien, J., Rashkova, I., Atun, R. A., & Yadav, P. (2014) · SSRN Electronic Journal · doi:10.2139/ssrn.2458038 · Cited by 6
Ocan, M., Nakalembe, L., Otike, C., Mordecai, T., Birungi, J., & Nsobya, S. (2024) · Malaria Journal · doi:10.1186/s12936-024-04956-5 · Cited by 5
Talisuna, A. O. (2014) · Malaria Chemotherapy Control and Elimination · doi:10.4172/2090-2778.1000117 · Cited by 5
Awor, P., & Kinengyere, A. A. (2023) · BMJ Public Health · doi:10.1136/bmjph-2023-000088 · Cited by 5
Liow, E., Kassam, R., & Sekiwunga, R. (2017) · Acta Tropica · doi:10.1016/j.actatropica.2017.06.008 · Cited by 5
Building Bridges for Collective Wisdom
Yu, P. P., & Vose, J. M. (2015) · Journal of Global Oncology · doi:10.1200/jgo.2015.000737 · Cited by 5
Maffioli, E. M., O’Meara, W. P., Turner, E. L., & Mohanan, M. (2017) · Review of Development Economics · doi:10.1111/rode.12708 · Cited by 3
Fulgheri, F., Manca, M. L., Fernàndez‐Busquets, X., & Manconi, M. (2023) · Nanomedicine · doi:10.2217/nnm-2023-0116 · Cited by 4
Patouillard, E., Kleinschmidt, I., Hanson, K., Pok, S., Palafox, B., Tougher, S., O’Connell, K., & Goodman, C. A. (2013) · Malaria Journal · doi:10.1186/1475-2875-12-311 · Cited by 4
Self-citationFerdiana, A., Cintyamena, U., Azizatunnisa’, L., Sunandar, E., & Probandari, A. N. (2021) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-021-00347-2 · Cited by 6
Ho, J., Odhiambo, G., Meng’anyi, L. W., Musuva, R., Mule, J., Alaly, Z., Odiere, M. R., Mwinzi, P. N. M., & Ganley-Leal, L. M. (2016) · BMC Health Services Research · doi:10.1186/s12913-016-1788-5 · Cited by 4
Lussiana, C., Floridia, M., do Rosário, J. M., Fortes, F., & Allan, R. J. (2016) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1093/trstmh/trw071 · Cited by 4
Aguèmon, B., Damien, G. B., Hinson, A. V., Padonou, G., Agbessinou, A. F. B., Ouendo, E. M., & Ayelo, P. A. (2018) · The Open Public Health Journal · doi:10.2174/1874944501811010054 · Cited by 4
Rotimi, K., Fagbemi, B., Itiola, A. J., Ibinaiye, T., Aidenagbon, A., Dabes, C., Biambo, A. A., Iwegbu, A., Onabajo, S., Oguoma, C., et al. (2023) · Journal of Pharmaceutical Policy and Practice · doi:10.1080/20523211.2023.2294024 · Cited by 3
Klein, E. Y., Smith, D. L., Cohen, J. M., & Laxminarayan, R. (2015) · Journal of The Royal Society Interface · doi:10.1098/rsif.2014.1356 · Cited by 3
Market for Artemether‐Lumefantrine to treat childhood malaria in a district of southern Mozambique
Alonso, S., Munguambe, K., & Sicuri, E. (2017) · Health Economics · doi:10.1002/hec.3514 · Cited by 3
Laktabai, J., Kimachas, E., Kipkoech, J., Menya, D., Arthur, D., Zhou, Y., Chepkwony, T. J., Abel, L., Robie, E. R., Amunga, M., et al. (2024) · PLOS Global Public Health · doi:10.1371/journal.pgph.0002451 · Cited by 3
Visser, T., Laktabai, J., Kimachas, E., Kipkoech, J., Menya, D., Arthur, D., Zhou, Y., Chepkwony, T. J., Abel, L., Robie, E. R., et al. (2024) · PLOS Global Public Health · doi:10.1371/journal.pgph.0002938 · Cited by 3
Evaluation of the Affordable Medicines Facility—malaria
Tozan, Y., Jahn, A., & Müller, O. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60756-4 · Cited by 3
Price Studies for Specific Medicines
Schneider, P. A., & Vogler, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813166-4.00008-5 · Cited by 2
Tougher, S., Hanson, K., & Goodman, C. A. (2021) · Health Economics · doi:10.1002/hec.4386 · Cited by 2
Self-citationHarnessing the Contribution of the Private Health Care Sector toward Public Health Goals
Montagu, D., Raman, A. V., & Sarker, M. (2022) · Cambridge University Press eBooks · doi:10.1017/9781009211086.028 · Cited by 2
Mookherji, S., & Meck, K. (2015) · Global Health Science and Practice · doi:10.9745/ghsp-d-14-00184 · Cited by 2
Is Affordability and Accessibility All It Takes?
Gregory, C., Ogundeji, M., Srivastava, A., Vanier, B., Dave, S., & Rampersad, A. (2019) · The Columbia University Journal of Global Health · doi:10.52214/thecujgh.v8i2.7828 · Cited by 2
Biting Back at Malaria: Assessing Health‐service Providers' Compliance with Treatment Guidelines
Paloyo, A. R., & Reichert, A. R. (2016) · Review of Development Economics · doi:10.1111/rode.12283 · Cited by 2
Iwuafor, A. A., Udoh, U. A., Ita, O. I., Ekeng, B. E., Irokanulo, U., & Abraka, B. A. (2019) · Saudi Journal of Pathology and Microbiology · doi:10.36348/sjpm.2019.v04i11.005 · Cited by 2
Commentary: Learning all the lessons: Expanding access to malaria diagnosis and treatment
von Schoen-Angerer, T. (2013) · Journal of Public Health Policy · doi:10.1057/jphp.2013.15 · Cited by 2
Evaluating complex interventions in international development
Masset, E., Shrestha, S., & Juden, M. (2021) · doi:10.51744/cmwp6 · Cited by 2
Osman, A., Johnson, F. A., Mariwah, S., Amoako-Sakyi, D., Owusu, S. A., Ekor, M., Hamill, H., & Hampshire, K. (2023) · BMJ Global Health · doi:10.1136/bmjgh-2023-013426 · Cited by 2
Accrombessi, M., ZINSOU, C., Woolheater, K., Ghyslain, G., Wang, E., Affoukou, C. D., Chabi, Y., Satchivi, J., Hurley, C., Poyer, S., et al. (2025) · doi:10.12688/verixiv.970.1 · Cited by 2
Ocan, M., Nambatya, W., Otike, C., Nakalembe, L., & Nsobya, S. (2024) · PLOS ONE · doi:10.1371/journal.pone.0295198 · Cited by 1
Ocan, M., Bakubi, R., Nakalembe, L., Ekusai‐Sebatta, D., & Sam, N. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297416 · Cited by 2
Modelling the returns on options for improving malaria case management in Ethiopia†
Gaumer, G. L., Zeng, W., & Nandakumar, A. K. (2013) · Health Policy and Planning · doi:10.1093/heapol/czt081 · Cited by 1
Improving estimation of ACT treatment coverage in Africa
Amuasi, J. (2017) · The Lancet Global Health · doi:10.1016/s2214-109x(17)30087-6 · Cited by 1
Self-citationIyengar, S., van den Ham, R., & Suleman, F. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813166-4.00007-3 · Cited by 1
Saran, I., Laktabai, J., Menya, D., Woolsey, A. M., Turner, E. L., Visser, T., & O’Meara, W. P. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-066814 · Cited by 1
Ayinbuomwan, S. A., Opadeyi, A. O., & Isah, A. (2022) · Babcock University Medical Journal · doi:10.38029/babcockunivmedj.v5i2.145 · Cited by 1
Joda, A. E., Ezeigwe, N., Oguguo, L., Taylor, O., & Ntadom, G. N. (2015) · PubMed Central · doi:10.5281/zenodo.10870094 · Cited by 1
Palafox, B., Goodman, C. A., & Hanson, K. (2019) · SSM - Population Health · doi:10.1016/j.ssmph.2019.100376 · Cited by 1
Self-citationProgram management issues in implementation of elimination strategies
Gosling, J., Case, P., Tulloch, J., Chandramohan, D., Gueye, C. S., Newby, G., Wegbreit, J., Koita, K., & Gosling, R. D. (2014) · Open Research Exeter (University of Exeter) · Cited by 1
Karimi, A. (2020) · University of Minnesota Digital Conservancy (University of Minnesota) · Cited by 1
Access to sexual and reproductive health medicines and supplies in Sub-Saharan Africa
Kibira, D. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/986 · Cited by 1
Gill, C. J., & Hamer, D. H. (2013) · Pathogens and Global Health · doi:10.1179/2047772413z.000000000122
Access, excess and ethics - towards a model for rational use of a new antibiotic -
Heyman, G. (2013) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Lemieux, P. B., Pribilsky, J., & Majors, I. P. (2014)
Maffioli, E. M., Turner, E. L., & Mohanan, M. (2017) · SSRN Electronic Journal · doi:10.2139/ssrn.2912940
Role of Donors in Global Health Supply Chains
Berenguer, G., & Rashkova, I. (2021) · Springer series in supply chain management · doi:10.1007/978-3-030-51957-5_4
Sorvillo, F. J., Shafir, S., & Bristow, B. N. (2015) · doi:10.1093/med/9780199661756.003.0215
Onwujekwe, O. E., Agwu, P., McKee, M., Odii, A., Orjiakor, C. T., Obodoechi, D. N., Nwokolo, C. C., Roy, P., Hutchinson, E., & Balabanova, D. (2025) · Journal of Health Management · doi:10.1177/09720634251370489
Accrombessi, M., ZINSOU, C., Woolheater, K., Ghyslain, G., Wang, E., Affoukou, C. D., Chabi, Y., Satchivi, J., Hurley, C., Poyer, S., et al. (2025) · doi:10.12688/verixiv.970.2
Ocan, M., Nambatya, W., Otike, C., Nakalembe, L., & Nsobya, S. (2023) · medRxiv · doi:10.1101/2023.11.17.23298706
Supply Chains as Health Infrastructure
Jacobs, A. E., Kapologwe, N., & Schwartz, J. I. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.12.030
Pharmacology for Physical Therapists
Balogun, S. T., Balogun, J. A., & Balogun, O. I. (2025) · Springer eBooks · doi:10.1007/978-3-031-86558-9_26
Esch, K., Woolheater, K., Accrombessi, M., Bouanchaud, P., Bouanchaud, P., ACTwatch Lite Group, Population Services International, W., & Population Services International, C. (2026) · doi:10.12688/verixiv.3070.1
From Black to Gray: Improving Access to Antimalarial Drugs in the Presence of Deceptive Counterfeits
Ding, J., Freeman, M., & Zorc, S. (2026) · Management Science · doi:10.1287/mnsc.2023.00885
Ajumobi, O., Meremikwu, M. M., Ezedinachi, E. N., & Ehiri, J. E. (2026) · Springer eBooks · doi:10.1007/978-1-0716-5432-3_3
Metadata
- Authors
- Tougher, S., Ye, Y., Amuasi, J. H., Kourgueni, I. A., Thomson, R., Goodman, C., Mann, A. G., Ren, R., Willey, B. A., Adegoke, C. A., Amin, A., Ansong, D., Bruxvoort, K., Diallo, D. A., Diap, G., Festo, C., Johanes, B., Juma, E., Kalolella, A., Malam, O., Mberu, B., Ndiaye, S., Nguah, S. B., Seydou, M., Taylor, M., Rueda, S. T., Wamukoya, M., Arnold, F., & Hanson, K.
- Affiliations
- London School of Hygiene & Tropical Medicine (GB)
- University of Minnesota (US)
- Ifakara Health Institute (TZ)
- ICF International (United States) (US)
- Komfo Anokye Teaching Hospital (GH)
- Drugs for Neglected Diseases Initiative (CH)
- Kenya Medical Research Institute (KE)
- African Population and Health Research Center (KE)
- Institut de Recherche pour le Développement (SN)
- Corresponding author
- Tougher, Sarah
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2012-12
- Volume
- 380
- Issue
- 9857
- Pages
- 1916-1926
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2122992752
- Cited by
- 173
- References
- 22
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 9 · 2023: 8 · 2022: 7 · 2021: 8 · 2020: 3 · 2019: 6 · 2018: 8 · 2017: 26 · 2016: 16 · 2015: 27 · 2014: 23 · 2013: 18 · 2012: 3
- FWCI
- 54.35
- Type
- journal article
- Language
- en
- Update notices
- erratum (2014-11-22)
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (submittedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Keywords
- Affordable Medicines Facility-malaria, artemisinin-based combination therapy, drug availability, market share, artemisinin monotherapy, drug subsidies, public sector, malaria treatment access, Global Fund, antimalarial drug resistance, Ghana, Kenya, Madagascar, Niger, Nigeria, Uganda, Tanzania
- MeSH terms
- Africa, Antimalarials, Humans, Lactones, Malaria, Marketing of Health Services, Pharmacies, Pilot Projects, Drug Costs, Private Sector, Public Sector, Artemisinins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
